Last updated: February 14, 2026
KLOXXADO (buprenorphine and naloxone) is an FDA-approved nasal spray indicated for treatment of opioid overdose in adults. It is branded by Vertice Pharma, Inc., with an initial approval date of December 2019.
Market Size and Growth Potential
Opioid Overdose Crisis Context
- The U.S. experienced approximately 68,000 opioid-related overdose deaths in 2020, up from 50,000 in 2019, according to CDC data [1].
- The market for opioid overdose reversal agents is driven by increasing overdose rates and expanding awareness of treatment options.
Current Demand Drivers
- Rising prevalence of opioid use disorder (OUD)
- Increased regulatory support and funding for overdose response programs
- Path to over-the-counter availability under certain conditions
Market Segments
- Emergency medical services
- Hospitals and clinics
- Pharmacists and pharmacies for community distribution
- Government programs targeting high-risk populations
Competitive Landscape
| Drug Name |
Formulation |
Approval Date |
Market Share |
Price (per dose) |
| KLOXXADO |
Nasal spray |
Dec 2019 |
Emerging |
$4,450 (wholesale) |
| Narcan (naloxone) nasal spray |
Nasal spray |
2015 |
Dominant |
$135 (retail) |
| Evzio (naloxone injection) |
Auto-injector |
2014 |
Penetrating |
$4,500 (wholesale) |
KLOXXADO has gained market traction due to its higher dosage (8 mg/4 mg) relative to Narcan, intended for opioid overdose reversal in heavy or resistant cases.
Market Growth Rate
- The global naloxone market was valued at approximately $900 million in 2021 and is projected to grow at over 8% CAGR through 2027 [2].
- The U.S. component dominates, with ongoing government procurement programs and institutional adoption.
Price Projections
Pricing Trends
- The wholesale acquisition cost (WAC) for KLOXXADO is roughly $4,450 per nasal spray device.
- Medicaid and Medicare reimbursements typically reflect discounts; retail prices for patients tend to be around $250–$400 per dose after pharmacy markup.
Pricing Dynamics
- Price stability is expected due to limited substitution options and regulatory barriers.
- Manufacturers may introduce generic versions post-expiration of patents, potentially reducing prices by 40-60% over 5-7 years [3].
Future Pricing Projections
| Timeframe |
Estimated Price Range |
Factors Influencing Price Changes |
| 2023–2024 |
$4,400–$4,600 |
Market penetration, supply chain stability, regulatory environment |
| 2025–2027 |
$3,000–$4,200 |
Entry of generics, increased competition, price negotiations |
| 2028+ |
$2,500–$3,500 |
Patent expiry, biosimilar entry, biosimilar regulatory approvals |
Implications for Stakeholders
- Payers may deploy formularies favoring lower-cost generics.
- Manufacturers may maintain premium pricing through branding and higher-dose formulations.
Regulatory and Policy Impact
- The Prescription Drug User Fee Act (PDUFA) influences approval, which impacts market entry timelines.
- Policy shifts favoring wide availability may increase market penetration, affecting pricing strategies.
- The SUPPORT Act and CDC recommendations support broader anti-overdose stocking, expanding volume but not necessarily affecting unit price significantly.
Key Takeaways
- KLOXXADO’s market is driven by the opioid crisis, with anticipated growth in demand.
- Current price points are high, with potential reductions as generics enter the market.
- Market share favors Narcan due to early entry and established distribution networks, but KLOXXADO's higher dosage could find specific niches.
- Pricing stability remains through proprietary formulation and limited competition; long-term, patent expiration may reduce costs.
- Regulatory policies and public procurement strategies will significantly influence pricing and availability.
FAQs
1. How does KLOXXADO compare to Narcan in terms of efficacy?
KLOXXADO contains a higher dose of buprenorphine, suitable for overdoses resistant to standard naloxone doses, but both effectively reverse opioid overdoses when used correctly.
2. What is the patent status of KLOXXADO?
The original patent expired or is close to expiration, opening potential for generics in the next 5–7 years.
3. Will government programs subsidize KLOXXADO?
Yes, public health agencies co-fund overdose reversal agents, which lowers costs for emergency services and community programs.
4. Can KLOXXADO be administered outside professional settings?
Yes, nasal spray formulations are designed for over-the-counter or pharmacy sale, making accessible non-medical users.
5. What are potential hurdles for market growth?
Pricing pressures, regulatory hurdles for OTC status, and competitive pricing from generics pose challenges.
Sources
[1] CDC. Drug overdose deaths in the United States, 2020.
[2] MarketsandMarkets. Naloxone market analysis, 2022.
[3] IQVIA. Pharmaceutical price analysis, 2023.
